ARTL
Artelo Biosciences, Inc.
Price Chart
Latest Quote
$1.31
+0.01 (+0.77%)
Current Price
| Previous Close | $1.30 |
| Open | $1.31 |
| Day High | $1.32 |
| Day Low | $1.29 |
| Volume | 65,013 |
Stock Information
| Shares Outstanding | 3.49M |
| Total Debt | $719K |
| Cash Equivalents | $10.27M |
| Net Income | $-13.46M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.74M |
| EPS (TTM) | $-29.01 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-6.38M |
| Income | $-13.46M |
| Book/sh | $7.62 |
| Cash/sh | $2.95 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.76 |
| Current Ratio | 1.79 |
| Debt/Eq | 10.78 |
Returns & Margins
| ROA | -91.33% |
| ROE | -367.69% |
Ownership
| Insider Ownership | 2.47% |
| Institutional Ownership | 8.10% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.55 |
| P/B | 0.18 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.42 |
| SMA50 | $3.13 |
| SMA200 | $6.90 |
| RSI | 56.49 |
| ATR | 0.1896 |
| Shares Float | 2.12M |
| Short Float | 6.28% |
| Short Ratio | 0.08 |
| Rel Volume | 0.10 |
Performance History
| Week | -1.45% |
| Month | -41.13% |
| Quarter | -63.83% |
| 6 Months | -76.14% |
| YTD | -64.30% |
| Year | -93.70% |
| 3 Years | -96.39% |
| 5 Years | -99.61% |
| 10 Years | -99.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $1.36 | 312,400 |
| 2026-06-11 | $1.32 | 234,500 |
| 2026-06-10 | $1.30 | 649,900 |
| 2026-06-09 | $1.33 | 203,600 |
| 2026-06-08 | $1.33 | 309,500 |
| 2026-06-05 | $1.38 | 287,500 |
| 2026-06-04 | $1.43 | 438,200 |
| 2026-06-03 | $1.46 | 266,200 |
| 2026-06-02 | $1.45 | 307,600 |
| 2026-06-01 | $1.43 | 554,900 |
| 2026-05-29 | $1.40 | 501,200 |
| 2026-05-28 | $1.46 | 982,800 |
| 2026-05-27 | $1.36 | 2,424,700 |
| 2026-05-26 | $1.71 | 26,034,000 |
| 2026-05-22 | $1.19 | 18,327,100 |
| 2026-05-21 | $1.33 | 302,200 |
| 2026-05-20 | $1.42 | 489,000 |
| 2026-05-19 | $1.36 | 289,400 |
| 2026-05-18 | $1.46 | 864,100 |
| 2026-05-15 | $1.84 | 8,612,800 |
| 2026-05-14 | $2.34 | 85,400 |
| 2026-05-13 | $2.31 | 59,500 |
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2026-03-27T14:30:19ZArtelo Biosciences announces 3-for-1 reverse stock split
TipRanks âĸ 2026-03-07T13:13:39Z
Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-09-08T13:49:11Z
Wall Street Weighs Payrolls, Jobless Claims Data, Driving Muted Premarket Action for US Equity Futures
MT Newswires âĸ 2025-09-04T13:08:02ZArtelo Biosciencesâ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study
Insider Monkey âĸ 2025-07-09T11:20:15Z
Sector Update: Health Care Stocks Advance Monday Afternoon
MT Newswires âĸ 2025-06-30T17:49:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $277,000 | $0 | $0 | $5,000 |
| Total Expenses | $11,404,000 | $10,108,000 | $9,930,000 | $10,287,000 |
| Other Income Expense | $-1,198,000 | $282,000 | $641,000 | $207,000 |
| Net Non Operating Interest Income Expense | $-277,000 | $0 | $0 | $-3,000 |
| Interest Expense Non Operating | $277,000 | $0 | $0 | $5,000 |
| Operating Expense | $11,404,000 | $10,108,000 | $9,930,000 | $10,287,000 |
| General And Administrative Expense | $5,981,000 | $4,115,000 | $4,234,000 | $5,963,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Net Interest Income | $-277,000 | $0 | $0 | $-3,000 |
| Normalized Income | $-11,681,000 | $-10,108,000 | $-9,930,000 | $-10,290,000 |
| Net Income From Continuing And Discontinued Operation | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Total Operating Income As Reported | $-11,404,000 | $-10,108,000 | $-9,930,000 | $-10,287,000 |
| Net Income Common Stockholders | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Net Income | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Net Income Including Noncontrolling Interests | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Net Income Continuous Operations | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Pretax Income | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Special Income Charges | $-1,158,000 | $0 | - | - |
| Operating Income | $-11,404,000 | $-10,108,000 | $-9,930,000 | $-10,287,000 |
| Interest Income | - | - | $0 | $2,000 |
| Interest Income Non Operating | - | - | $0 | $2,000 |
| Per Share | ||||
| Diluted EPS | $-37.56 | $-54.90 | $-56.52 | $-64.08 |
| Basic EPS | $-37.56 | $-54.90 | $-56.52 | $-64.08 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,404,000 | $-10,108,000 | $-10,571,000 | $-10,285,000 |
| Total Unusual Items | $-1,198,000 | $282,000 | $641,000 | $207,000 |
| Total Unusual Items Excluding Goodwill | $-1,198,000 | $282,000 | $641,000 | $207,000 |
| EBITDA (Bullshit earnings) | $-12,602,000 | $-9,826,000 | $-9,930,000 | $-10,078,000 |
| EBIT | $-12,602,000 | $-9,826,000 | $-9,930,000 | $-10,078,000 |
| Diluted Average Shares | $342,999 | $178,999 | $164,444 | $157,388 |
| Basic Average Shares | $342,999 | $178,999 | $164,444 | $157,388 |
| Diluted NI Availto Com Stockholders | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $1,158,000 | - | - | - |
| Gain On Sale Of Security | $-40,000 | $282,000 | $641,000 | $207,000 |
| Research And Development | $5,423,000 | $5,993,000 | $5,696,000 | $4,324,000 |
| Selling General And Administration | $5,981,000 | $4,115,000 | $4,234,000 | $5,963,000 |
| Other Gand A | $5,981,000 | $4,115,000 | $4,234,000 | $5,963,000 |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-3,311,000 | $818,000 | $9,713,000 | $17,364,000 |
| Total Assets | $2,801,000 | $4,698,000 | $13,043,000 | $20,424,000 |
| Total Non Current Assets | $2,106,000 | $2,141,000 | $2,063,000 | $2,102,000 |
| Other Non Current Assets | $3,000 | $3,000 | $3,000 | $3,000 |
| Goodwill And Other Intangible Assets | $2,039,000 | $2,039,000 | $2,039,000 | $2,039,000 |
| Other Intangible Assets | $2,039,000 | $2,039,000 | $2,039,000 | $2,039,000 |
| Current Assets | $695,000 | $2,557,000 | $10,980,000 | $18,322,000 |
| Other Current Assets | $95,000 | $219,000 | $554,000 | $789,000 |
| Cash Cash Equivalents And Short Term Investments | $600,000 | $2,338,000 | $10,426,000 | $17,533,000 |
| Cash And Cash Equivalents | $600,000 | $2,338,000 | $2,815,000 | $6,888,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $9,000 | - | - | - |
| Total Debt | $678,000 | $104,000 | $23,000 | $63,000 |
| Long Term Debt And Capital Lease Obligation | $29,000 | $69,000 | $0 | $23,000 |
| Current Debt And Capital Lease Obligation | $649,000 | $35,000 | $23,000 | $40,000 |
| Current Debt | $609,000 | - | - | - |
| Other Current Borrowings | $609,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,073,000 | $1,841,000 | $1,291,000 | $1,021,000 |
| Total Non Current Liabilities Net Minority Interest | $29,000 | $69,000 | $0 | $23,000 |
| Current Liabilities | $4,044,000 | $1,772,000 | $1,291,000 | $998,000 |
| Payables And Accrued Expenses | $3,395,000 | $1,737,000 | $1,268,000 | $958,000 |
| Interest Payable | $15,000 | $0 | - | - |
| Payables | $3,380,000 | $1,737,000 | $1,268,000 | $958,000 |
| Accounts Payable | $3,035,000 | $1,676,000 | $1,238,000 | $905,000 |
| Other Current Liabilities | - | $-3,000 | - | - |
| Equity | ||||
| Common Stock Equity | $-1,272,000 | $2,857,000 | $11,752,000 | $19,403,000 |
| Total Equity Gross Minority Interest | $-1,272,000 | $2,857,000 | $11,752,000 | $19,403,000 |
| Stockholders Equity | $-1,272,000 | $2,857,000 | $11,752,000 | $19,403,000 |
| Gains Losses Not Affecting Retained Earnings | $-272,000 | $-202,000 | $-203,000 | $-254,000 |
| Other Equity Adjustments | $-272,000 | $-202,000 | $-203,000 | $-254,000 |
| Retained Earnings | $-63,015,000 | $-50,136,000 | $-40,310,000 | $-31,021,000 |
| Other | ||||
| Ordinary Shares Number | $673,007 | $189,194 | $177,164 | $158,649 |
| Share Issued | $673,007 | $189,194 | $177,164 | $158,649 |
| Tangible Book Value | $-3,311,000 | $818,000 | $9,713,000 | $17,364,000 |
| Invested Capital | $-663,000 | $2,857,000 | $11,752,000 | $19,403,000 |
| Working Capital | $-3,349,000 | $785,000 | $9,689,000 | $17,324,000 |
| Capital Lease Obligations | $69,000 | $104,000 | $23,000 | $63,000 |
| Total Capitalization | $-1,272,000 | $2,857,000 | $11,752,000 | $19,403,000 |
| Additional Paid In Capital | $62,013,000 | $53,194,000 | $52,262,000 | $50,675,000 |
| Capital Stock | $2,000 | $1,000 | $3,000 | $3,000 |
| Common Stock | $2,000 | $1,000 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $29,000 | $69,000 | $0 | $23,000 |
| Current Capital Lease Obligation | $40,000 | $35,000 | $23,000 | $40,000 |
| Current Accrued Expenses | $15,000 | $0 | - | - |
| Dueto Related Parties Current | $345,000 | $61,000 | $30,000 | $53,000 |
| Net PPE | $64,000 | $99,000 | $21,000 | $60,000 |
| Gross PPE | $64,000 | $99,000 | $21,000 | $60,000 |
| Other Properties | $64,000 | $99,000 | $21,000 | $60,000 |
| Other Short Term Investments | - | $0 | $7,611,000 | $10,645,000 |
| Treasury Shares Number | - | - | $0 | - |
| Buildings And Improvements | - | - | $21,000 | $60,000 |
| Properties | - | - | $0 | $0 |
| Investments And Advances | - | - | - | $0 |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,520,000 | $-8,350,000 | $-8,207,000 | $-8,008,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,520,000 | $-8,350,000 | $-8,207,000 | $-8,008,000 |
| Cash Flow From Continuing Operating Activities | $-8,520,000 | $-8,350,000 | $-8,207,000 | $-8,008,000 |
| Operating Gains Losses | $1,220,000 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-62,000 | $7,769,000 | $3,507,000 | $2,958,000 |
| Cash Flow From Continuing Investing Activities | $-62,000 | $7,769,000 | $3,507,000 | $2,958,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $6,151,000 | $112,000 | $567,000 | $0 |
| Financing Cash Flow | $6,867,000 | $112,000 | $567,000 | $0 |
| Cash Flow From Continuing Financing Activities | $6,867,000 | $112,000 | $567,000 | $0 |
| Net Common Stock Issuance | $6,151,000 | $112,000 | $567,000 | $0 |
| Common Stock Issuance | $6,151,000 | $112,000 | $567,000 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-24,000 | $0 | - | - |
| Issuance Of Debt | $608,000 | $0 | - | - |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $600,000 | $2,338,000 | $2,815,000 | $6,888,000 |
| Beginning Cash Position | $2,338,000 | $2,815,000 | $6,888,000 | $12,162,000 |
| Effect Of Exchange Rate Changes | $-23,000 | $-8,000 | $60,000 | $-224,000 |
| Changes In Cash | $-1,715,000 | $-469,000 | $-4,133,000 | $-5,050,000 |
| Proceeds From Stock Option Exercised | $132,000 | $0 | - | $0 |
| Net Issuance Payments Of Debt | $584,000 | $0 | - | - |
| Net Short Term Debt Issuance | $584,000 | $0 | - | - |
| Short Term Debt Payments | $-24,000 | $0 | - | - |
| Short Term Debt Issuance | $608,000 | $0 | - | - |
| Net Investment Purchase And Sale | $-62,000 | $7,769,000 | $3,507,000 | $2,958,000 |
| Sale Of Investment | $188,000 | $8,250,000 | $17,192,000 | $16,182,000 |
| Purchase Of Investment | $-250,000 | $-481,000 | $-13,685,000 | $-13,224,000 |
| Change In Working Capital | $1,789,000 | $937,000 | $703,000 | $-172,000 |
| Change In Payables And Accrued Expense | $1,660,000 | $480,000 | $273,000 | $23,000 |
| Change In Accrued Expense | $69,000 | $0 | - | - |
| Change In Interest Payable | $69,000 | $0 | - | - |
| Change In Payable | $1,591,000 | $480,000 | $273,000 | $23,000 |
| Change In Account Payable | $1,591,000 | $480,000 | $273,000 | $23,000 |
| Change In Prepaid Assets | $129,000 | $457,000 | $430,000 | $-195,000 |
| Other Non Cash Items | $208,000 | $3,000 | - | $-4,000 |
| Stock Based Compensation | $1,142,000 | $818,000 | $1,020,000 | $2,458,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-282,000 | $-641,000 | $-207,000 |
| Gain Loss On Investment Securities | $62,000 | - | - | - |
| Net Income From Continuing Operations | $-12,879,000 | $-9,826,000 | $-9,289,000 | $-10,083,000 |
Fetched: 2026-06-06